drugset / Trial / NCT01879748

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

NCT01879748

Phase 1 Completed 64 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the pharmacokinetics of rasagiline in healthy Japanese and Caucasian subjects after single and multiple doses of rasagiline.

Timeline

Start
2013-06
Primary completion
2013-09
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 0.5 mg Oral
Subject Rasagiline Small molecule 1 mg Oral
Subject Rasagiline Small molecule 2 mg Oral

Indications